Patty Maysent, MPH, MBA, has been appointed interim Chief Executive Officer of UC San Diego Health, bringing to the role more than 25 years of exceptional executive experience in hospital leadership and health services management.
The Clinical and Translational Research Institute (CTRI) at University of California, San Diego has received a five-year Clinical and Translational Science Award (CTSA) for approximately $52 million from the National Center for Advancing Translational Science, part of the National Institutes of Health.
The introduction of a new prescription smoking-cessation aid, varenicline, in 2006 has had no significant impact on the rate at which Americans age 18 and older successfully quit smoking, according to a study led by researchers at University of California, San Diego School of Medicine. The findings, published online August 17 in Tobacco Control, suggest that the primary effect of varenicline has been to displace the use of older tobacco addiction therapies, such as nicotine patches and the antidepressant, bupropion.
Protein Kinase C is a family of enzymes that controls the activity of other proteins in a cell by attaching chemical tags. That simple act helps determine cell survival or death. When it goes awry, a number of diseases may result. In a study, researchers at University of California, San Diego School of Medicine reveal a more accurate structure of PKC, providing new targets for fine-tuning the enzyme’s activity as needed to improve human health.
The mechanisms that allow the liver to repair and regenerate itself have long been a matter of debate. Now researchers at University of California, San Diego School of Medicine have discovered a population of liver cells that are better at regenerating liver tissue than ordinary liver cells, or hepatocytes. The study is the first to identify these so-called “hybrid hepatocytes,” and show that they are able to regenerate liver tissue without giving rise to cancer.
Donald L. Durden, MD, PhD, pediatric researcher at University of California, San Diego School of Medicine and Moores Cancer Center has identified and developed a novel therapeutic target for neuroblastoma, the second most common solid-tumor childhood cancer. The agent, named SF1126, acts by inhibiting the part of the cancer cell engine that promotes tumor angiogenesis and growth.
U.S. News & World Report, June 9
Women's Health, June 3
The New York Times, June 2
The San Diego Union-Tribune, May 23
Keep up with all the latest from UC San Diego. Subscribe to the newsletter today.
